RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

BackgroundImmunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (combinations) are warranted. Simultaneously, risk asse...

Full description

Bibliographic Details
Main Authors: Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Immunology
Subjects:
multiple myeloma
immunotherapeutic targets
personalized treatment
risk-adapted treatment
RNA-sequencing
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1286700/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1286700/full

Similar Items